Study May Boost Use of Merck Lung-Cancer Drug

Patients with advanced lung cancer who took Merck ’s immune-boosting drug Keytruda as their first treatment lived longer on average than those who received chemotherapy, a new study shows.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: FREE Source Type: news
More News: Pharmaceuticals